Literature DB >> 18039466

Nanog inhibits the switch of myogenic cells towards the osteogenic lineage.

Bose S Kochupurakkal1, Rachel Sarig, Ora Fuchs, Dan Piestun, Gidi Rechavi, David Givol.   

Abstract

The homeodomain transcription factor Nanog has been implicated in inhibiting differentiation and controlling pluripotency of embryonic stem (ES) cells. We used ectopic expression of Nanog in the myogenic committed C2 cells to dissect these properties. Expression of Nanog in C2 cells does not alter terminal muscle differentiation but has a profound effect on their switch to differentiate along the osteogenic lineage upon BMP treatment. Gene expression profiling revealed that ERK 1/2 phosphorylation, alkaline-phosphatase activity and osteocalcin expression were induced to much lower extent and remained suppressed even after 96h. in Nanog expressing C2 cells, compared to control C2 cells. Hence, Nanog does not inhibit terminal differentiation of committed cells but it is an inhibitor of trans-differentiation that is dependent on de-novo activation of gene transcription.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039466     DOI: 10.1016/j.bbrc.2007.11.073

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Magnetofection Mediated Transient NANOG Overexpression Enhances Proliferation and Myogenic Differentiation of Human Hair Follicle Derived Mesenchymal Stem Cells.

Authors:  Seoyoung Son; Mao-Shih Liang; Pedro Lei; Xiaozheng Xue; Edward P Furlani; Stelios T Andreadis
Journal:  Bioconjug Chem       Date:  2015-03-10       Impact factor: 4.774

2.  Runx1 and Runx3 Are Downstream Effectors of Nanog in Promoting Osteogenic Differentiation of the Mouse Mesenchymal Cell Line C3H10T1/2.

Authors:  Tadahito Saito; Shinsuke Ohba; Fumiko Yano; Ichiro Seto; Yoshiyuki Yonehara; Tsuyoshi Takato; Toru Ogasawara
Journal:  Cell Reprogram       Date:  2015-06       Impact factor: 1.987

3.  Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.

Authors:  Rachel Sarig; Noa Rivlin; Ran Brosh; Chamutal Bornstein; Iris Kamer; Osnat Ezra; Alina Molchadsky; Naomi Goldfinger; Ori Brenner; Varda Rotter
Journal:  J Exp Med       Date:  2010-08-09       Impact factor: 14.307

4.  Nanog reverses the effects of organismal aging on mesenchymal stem cell proliferation and myogenic differentiation potential.

Authors:  Juhee Han; Panagiotis Mistriotis; Pedro Lei; Dan Wang; Song Liu; Stelios T Andreadis
Journal:  Stem Cells       Date:  2012-12       Impact factor: 6.277

5.  The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.

Authors:  Y Shetzer; S Kagan; G Koifman; R Sarig; I Kogan-Sakin; M Charni; T Kaufman; M Zapatka; A Molchadsky; N Rivlin; N Dinowitz; S Levin; G Landan; I Goldstein; N Goldfinger; D Pe'er; B Radlwimmer; P Lichter; V Rotter; R Aloni-Grinstein
Journal:  Cell Death Differ       Date:  2014-05-16       Impact factor: 15.828

6.  Transcriptional analysis of fracture healing and the induction of embryonic stem cell-related genes.

Authors:  Manish Bais; Jody McLean; Paola Sebastiani; Megan Young; Nathan Wigner; Temple Smith; Darrell N Kotton; Thomas A Einhorn; Louis C Gerstenfeld
Journal:  PLoS One       Date:  2009-05-05       Impact factor: 3.240

7.  p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.

Authors:  Alina Molchadsky; Igor Shats; Naomi Goldfinger; Meirav Pevsner-Fischer; Melissa Olson; Ariel Rinon; Eldad Tzahor; Guillermina Lozano; Dov Zipori; Rachel Sarig; Varda Rotter
Journal:  PLoS One       Date:  2008-11-12       Impact factor: 3.240

8.  Nanog1 in NTERA-2 and recombinant NanogP8 from somatic cancer cells adopt multiple protein conformations and migrate at multiple M.W species.

Authors:  Bigang Liu; Mark D Badeaux; Grace Choy; Dhyan Chandra; Irvin Shen; Collene R Jeter; Kiera Rycaj; Chia-Fang Lee; Maria D Person; Can Liu; Yueping Chen; Jianjun Shen; Sung Yun Jung; Jun Qin; Dean G Tang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.